Levocin (Levofloxacin)

Levofloxacin blocks bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes required for DNA replication and transcription. By preventing DNA strand unwinding and resealing, it stops bacterial cell division, leading to a bactericidal effect against susceptible organisms.

The exact dose of Levocin is set by the prescribing clinician based on the infection type, severity, patient age, renal function, and any concomitant medications. Dosage adjustments may be required for patients with reduced kidney function.

Levofloxacin is classified as pregnancy category unknown, and safety data are limited. It is generally avoided during pregnancy and lactation unless the potential benefit outweighs the risk. Physicians should evaluate each case individually.

To order Levocin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Levocin (levofloxacin) offers once‑daily dosing and a broad spectrum covering many Gram‑negative and Gram‑positive bacteria, often providing a convenient alternative to older fluoroquinolones such as ciprofloxacin. Compared with macrolides or beta‑lactams, it may achieve higher tissue penetration but shares class‑related safety considerations.

Levocin tablets should be stored at ambient temperature, preferably below 25 °C, in the original packaging to protect from moisture and light. Keep the product out of reach of children and do not use after the expiration date.

Levocin is supplied as an oral tablet and is taken by mouth with or without food, as directed by the prescriber. Swallow the tablet whole with a full glass of water; do not crush or chew unless specifically instructed.

Serious risks include tendon rupture or tendonitis, especially in older adults or those on corticosteroids; QT interval prolongation that can lead to life‑threatening arrhythmias; and severe hypersensitivity reactions such as anaphylaxis or Stevens‑Johnson syndrome. Prompt medical attention is required if these events occur.

Levocin should be avoided in patients with a known hypersensitivity to levofloxacin or other fluoroquinolones, those with a history of tendon disorders related to fluoroquinolone use, and individuals with significant QT prolongation or uncontrolled cardiac arrhythmias. Caution is also advised for patients with severe renal impairment.